Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria

Activity Overview

Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.

0.25 CE Credit(s)
Expires: April 18, 2023

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
  • Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
  • Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Faculty

Jonathan-Bernstein-300px

Jonathan A. Bernstein, MD

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Provider Statement

This activity is provided by RMEI Medical Education, LLC

Supporter Statement

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources